Summary
Introduction
Acquired immunodeficiency syndrome (AIDS) is a retroviral disease of pandemic proportions. Worldwide more than 200 million individuals are infected with the human immunodeficiency virus (HIV). Despite a vigorous immune response on the part of the host, HIV infection leads to the gradual destruction of the immune system, primarily by depleting CD4 T lymphocytes in infected hosts. HIV viral isolates replicate most efficiently in activated CD4 T cells. In patients, CD4 T cells carry the majority of the viral load (Seshamma et al., 1992) . To explain the paradox of a virus eliminating its own cellular reservoir, one may invoke other cellular reservoirs such as monocytes, dendritic cells, or follicular dendritic cells in lymph nodes, which might act as a source of infectious virions to infect new CD4 T cells (Pantaleo et al., 1993; Embretson et al., 1993; Cameron et al., 1992) . However, at least in peripheral blood and lymph nodes, the predominant host cell in which HIV-1 DNA is found is the CD4 T cell (Schnittman et al., 1989; Embretson et al., 1993) .
An alternative possibility is that some CD4 T cells do act as a reservoir and are not deleted. Recently, HIV-1 DNA and infectious virus were found specifically concentrated in a tiny subset (10-2o) of CD4 T cells in many infected patients (Dobrescu et al., 1995) . This subset expressed T cell antigen receptors (TCRs) using the V!B12 gene segment. For instance, in 16 of 23 HIV-infected patients there was a 2-to 360-fold higher viral load in fresh, uncultured V~12 cells than in control V~6.7a cells (Dobrescu et al., 1995) . HIV-1 in VI312 cells of patients was competent in an infectivity assay (Dobrescu et al., 1995) . Moreover, irradiated non-T cells from HIV-infected patients stimulated proliferation of V~12 but not V~6.7a cell lines (Laurence et al., 1992) . In addition, HIV-I replicates approximately 100-fold more efficiently in interleukin 2 (IL-2)-dependent T cell lines expressing TCR VI312 rather than other VI~ genes, regardless of the major histocompatibility complex (MHC) type of the cells (Laurence et al., 1992) . HIV-1 replication occurred preferentially in V~12 T cells, as compared with 11 other VI3 subsets, from normal fresh peripheral blood mononuclear cells cultured for 6-8 days with IL-2 (Dobrescu et ai., 1995) . Therefore the V1~12 subset serves as a preferential host cell for HIV-1 replication, possibly because it is activated by a superantigen (SAG)-Iike moiety presented to T cells by MHC class IIexpressing non-T cells.
SAGs are a group of microbial proteins known for their potent ability to activate large numbers of T cells that share common TCR V~ expression, and this is typically independent of the MHC class II alleles used by antigen-presenting cells. Mouse mammary tumor viruses (MMTVs) are B-type retroviruses that encode the prototypic viral SAG in the 3' long terminal repeat. The SAG directly supports the initial stages of viral infection after vertical transmission via maternal milk. The SAG bridges antigen-presenting cells bearing MHC class II and large numbers of T cells expressing specific VI~ genes. It is thought that both cell types transduce signals as a consequence and the net effect is massive immune activation with high levels of lymphokines produced (Chatila and Geha, 1993) . As a direct consequence, MMTV replication in infected B cells is upregulated, and cellular proliferation of virally infected B cells accounts for a 4000-fold increase in the number of infected B cells by clonal expansion (Held el: al., 1993 (Held el: al., , 1994 .
While previous studies suggested the presence of an HIV-1 associated SAG (Laurence et al., 1992; Dobrescu et al., 1995) , they did not establish the source of the putative SAG gene: HIV-1 itself, a ubiquitous virus, and the host cell were all equally likely alternatives (Posnett et al., 1993a) . Here, we provide evidence that the V~12-specific SAG is produced by cytomegalovirus (CMV)-infected monocytes, that its production is driven by CMV infection even in the absence of HIV-1, and that CMV antibodies in patients positive for HIV-1 are associated with an HIV-1 reservoir in VI312 cells.
Results

Vp12-Selective HIM-1 Replication Resembles the Effect of Known SAGs
HIV-1 replication in V~12 cell lines required the presence of non-T cells and was inhibited with anti-M HC II antibodies (Laurence et al., 1992) . Selective HIV replication in the The non-T cells were previously exposed to the mitogen NalO4 or were not. After 7 days, the indicated V~ subsets were positively selected or depleted (minus) with magnetic beads prior to cell lysis and PCR.
(C) HIV-infected T cells were cocultured with autologous non-T cells pulsed with mycoplasma arthritidis mitogen (MAM) (Bhardwaj et al., 1994) or with DAP-DR1 transfectants expressing MTV7 or MTV9 (Labrecque et al., 1993) . Dilutions of the PCR product are indicated.
VI512 subset of freshly infected normal T cells cultured for 6-8 days with IL-2 also required non-T cells (Dobrescu et al., 1995) . To examine the effect of different sources of non-T cells, fresh T cells from a normal adult donor were infected with HIV-1 (TIIIB, multiplicity of infection [moi], 0.05) and cultured with autologous non-T cells or allogeneic non-T cells (plus or minus prior treatment with NalO4) for 7 days. HIV-1 replication, measured by semi-quantitative polymerase chain reaction (PCR) in isolated VI~ subsets, occurred preferentially in VI312 cells in three of four conditions (Figure 1 B) . Normalized for cell numbers, there were approximately 100-fold more viral gag copies in VI312 cells compared with control subsets ( Figure 2B ). The same pattern of V~-selective HIV-1 replication was also observed with known SAGs ( Figure 1C ): mycoplasma arthritidis mitogen, which targets V1~17 T cells (Friedman et al., 1991) , or MMTV SAGs of mammary tumor virus 7 (MTV7) and MTV9, which target human V~12 and V~6.7a subsets, respectively (Labrecque et al., 1993) . In each case, the SAGtargeted VI3 subset contained 10-to 100-fold greater numbers of HIV-1 copies per 1000 cells ( Figure 2C ). These measurements are normalized for cell numbers and therefore underestimate the total impact of the SAG on the viral load, as SAGs are known to expand cell numbers of the targeted Vl5 subset in short-term cultures (Kappler et al., 1989; Friedman et al., 1991; Labrecque et al., 1993) . Figures 2A and 2C contain controls in which the ratio of HIV-1 per total cell number remains constant through serial 5-fold dilutions, indicating the degree of experimental variation in the measurements and demonstrating that the ratios are independent of the total numbers of cells in each positively selected VI~ subset.
Vp12-Selective HIM-1 Replication Depends on the Presence of Monocytes from CMV-Seropositive Donors
Any MHC class II-positive cell is thought to be capable of presenting a SAG to T cells. However, in Figure 3 , we show that only CD14 + monocytes were capable of supporting selective HIV-1 replication in V~12 cells. CD19 ÷ B cells and CD19-14-dendritic cells were insufficient, although both express MHC class II and can present exogenous SAG. Dendritic cells are particularly efficient at presenting SAGs to T cells (Bhardwaj et al., 1992) . Epstein-Barr virus-transformed B cell lines were also ineffective (data not shown). Since monocytes from normal adults are often persistently infected with human CMV (Taylor-Wiedeman et al., 1991 ; Soderberg et al., 1993) and can express immediate-early genes of CMV after in vitro culture (Ibanez et al., 1991; Taylor-Wiedeman et al., 1994) , we considered the possibility that CMV was the source of the SAG. Non-T cells were able to promote selective HIV-1 replication in V~12 cells, as shown in Figure 1B , only when obtained from CMV-seropositive donors (Table 1) . Non-T cells from human cord blood and from CMV-negative adult donors were unable to stimulate HIV-1 replication in V~12 cells, even when the non-T cells had received prior treatment with the mitogen NalO4 (see Experimental Procedures) or when an allogeneic combination of non-T cells and HIV-infected T cells was used (Table 1; Figure 4 ). CMV-negative cord blood non-T cells were perfectly capable of presenting an exogenous SAG (mycoplasma arthritidis mitogen), resulting in HIV-1 replication in the targeted V~17 subset (Friedman et al., 1991) (data not shown).
Several CMV Isolates Can Stimulate HIV-1 Replication in Vl~12 Cells
The monocyte-like cell line, U937, is permissive for CMV infection (Numazaki et al., 1992) and expresses low levels of HLA-DR5 (data not shown). These cells do not contain endogenous CMV and transcribe CMV immediate-early genes (immediate-early 1 [iel] and ie2) within 24 hr after infection (see Figures 9B and 9C; data not shown). U937 cells were infected with CMV (moi, 1) in a 3-day culture followed by treatment with mitomycin C to inhibit further cellular proliferation. The CMV-infected U937 cells were then added, at a 1:10 ratio, to freshly isolated normal T cells infected in vitro with HIV-1. CMV-infectecl U937 cells Table 1 Non-T cells were isolated from donors that had been serologically tested (by enzyme-linked immunosorbent assay) for antibodies to CMV. The irradiated cells were cocultured under four different conditions with HIV-infected T cells. PCR was performed on isolated V~ subsets after 6-8 days (as in Figure 1B ). Indicated are the percentage of donors with non-T cells that support V~12-selective HIV.1 replication.
efficiently stimulated selective HIV-1 replication in VI312 cells, but uninfected U937 cells or NalO4-treated U937 cells did not (Figures 4-6 ). The CMV effect was not dependent on the viral isolate used (Figure 4 ). Laboratory strain AD169 and clinical isolates 1165 and 2830 were equally capable of stimulating H IV-1 replication in VI312 T cells from CMV-negative donor (MU) and cord blood (CB).
Up-regulated HIV-1 replication in VI512 cells was observed with three unrelated HIV-1 isolates: TIlIB, JRFL, and BaL ( Figure 5 ; data not shown). HIV-1 replication occurs predominantly in the VI312 subset, since VI312-depleted cells showed significantly decreased viral replication compared with VI317-depleted cells ( Figure 5 ).
The CMV effect could no longer be observed when the CMV viral stock was inactivated by exposure to ultraviolet (UV) light prior to infection of U937 cells ( Figure 6A ). CMV DNA replication is usually initiated 2-3 days after infection (reviewed by Mocarski, 1993) . Since U937 cells were harvested 3 days after CMV infection and then treated with mitomycin C, which inhibits DNA replication, the effect on V1~12 cells was expected to be independent of CMV DNA replication. In fact, addition of phosphonoformic acid (Foscarnet), a specific inhibitor of CMV DNA replication, or acyclovir to CMV-infected U937 cells did not inhibit the SAG-like effect ( Figure 6A ). Finally, cycloheximide, added 12 hr prior to harvesting CMV-infected U937 cells, partially inhibited the SAG-like effect in a dose-dependent manner ( Figure 6A ). Protein synthesis in CMV-infected U937 cells was therefore required to observe the Vl312-specific SAG activity. Figure 6A ). Moreover, addition of recombinant tumor necrosis factor (~ (TNF(~), a monocyte cytokine known to up-regulate HIV-1 replication potently (Clouse et al., 1989a (Clouse et al., , 1989b Hober et al., 1992) , induced replication in all three VI5 subsets examined, rather than in a VI512-selective pattern, and antibody to TNFa did not inhibit the effect of CMV-infected U937 cells ( Figure 6B ).
The transwells were separated by a 0.3 ilm filter. The result in Figure 6A , therefore, argues against the possibility that CMV virions (150-200 nm) are transmitted from U937 to T cells and that CMV and HIV-1 might coinfect the same host cells. In fact, CMV DNA could not be found by PCR in isolated VI312 cells or other VI3 subsets after a 7-day coculture of T cells with CMV-infected U937 cells (data not shown).
CMV-Infected U937 Cells Stimulate Vp12 CD4 ÷ and V1~12 CD8 + Cells to Expand In Vitro
SAGs added to T cell cultures produce an expansion of the targeted VI3 subsets (Kappler et al., 1989; et al., 1991) . Therefore, we analyzed the percentage of V~ 12 cells in cocultures of HIV-l-infected T cells with autologous NalO4-treated non-T cells from a CMV-positive donor. Uncultured fresh CD3÷CD4 ÷ cells contained 2% V~12 cells. After 7 days, there were 18% Vl~12 cells (data not shown). Next, normal T cells were cultured with either U937 or CMV-infected U937 cells in the absence of HIV-1 for 6 days and then stained. There were 1.5% versus 8.1% VI~ 12 per total CD3 cells, respectively, as assayed with two different V1312-specific monoclonal antibodies (MAbs) (Figure 7 ). There was no increase in the' percentages of three other V~ subsets. The relative expansion of the VI312 subset involved both CD4 and CD8 cells. This result argues in favor of a SAG response as opposed to a peptide-MHC response, which would be either class I or class II restricted and would therefore involve either CD8 or CD4 cells, but not both. Moreover, this extent of specific expansion of a VI~ subset is not expected in responses to nominal peptide antigens. 
Evidence of a VJ~12-Specific S A G In Vivo in C M V -I n f e c t e d Patients
A group of 23 HIV-l-infected patients was studied using HIV-1 gag DNA semi-quantitative PCR (Dobrescu et al., 1995) (Table 2 ). About two thirds of these patients had a 2-to 360-fold higher viral load in V1312 than in V~6.7a cells.
In several patients, HIV-1 DNA was selectively present in VJ312 cells at repeated timepoints. For example, in patient M3 the viral load is strongly skewed to the V~12 and V[35.2/3 subsets, while several other V~ subsets lack detectable HIV-1 gag (Figure 8 ). This is not due to variable cell numbers in the positively selected V~ subsets, as the HLA-DQ bands are similar and the VI3 subsets assessed by flow cytometry are comparable (the range is 1 % -6 % of CD3+CD4 ÷ T cells). The V~12 subset is one of the smaller subsets in this patient ( 1 % -2 % of CD3+CD4 ÷ T cells). It is unknown whether the relatively high HIV-1 copy number in the VI35.2/3 subset is a consistent finding in this patient• It is not related to the CMV SAG response, since we had Figure 6 . The CMV Effect on HIV-1 Replication in V~12 Cells Is Not Due to TNFa, Requires Cell-Cell Contact, and Requires Live CMV and Protein Synthesis in CMWlnfected Host Cells, but Does Not Require CMV DNA Replication (A) HIV-l-infected T cells were cocultured for 7 days with U937 cells. In conditions 3 and 4, U937 cells were separated from the T cells in a transwell system (0.3 p.m filter; Costar). In 5, the CMV viral stock was UV irradiated (1 J/cm 2 i~g,'ml mpg/ml UV-C at 254 nm). U937 cells were infected with : ~ ~ ~ 01 ~ ~ ~ CMV AD169 and cultured for 3 days in the pres-=. > > > > > > ence of Foscarnet 100 pg/ml (condition 6) or ' U937 U937 0.1 mM acyclovir (condition 7). Cycloheximide ~9 +AD169 +AD169 vi, CHX CHX (CHX) was added to AD169-infected U937 cells 8 9 for the last 12 hr of the 3-day culture (8 and 9). (B) HiV-l-infected cord blood T cells were cultured for 7 days with U937 cells treated with NalO4 (11) or with CMV AD169-irffected U937 cells (12) (13) (14) , to which were added rabbit anti-TNF~ (30 ng/ml; Sigma)(12), rabbit i mmunoglobulin (30 ng/ml) (13), or exogenous human recombinant TNFa (10 ng/ml; R&D Systems) (14). Fresh T cell from an HIV-l-negative donor were cocultured with U937 or CMV-infected U937 cells at a 10:1 ratio. After 7 days, the cells were stained by two-color immunofluorescence with CD3-PE, CD4oPE, or CD8-PE and VI~ MAbs indirectly labeled with goat anti-mouse Ig-fluorescein isothiocynate (Posnett et al., 1993b) .
previously examined this subset in in vitro cultures, as in Figure 1 , without observing high level HIV-1 viral replication (Dobrescu et al., 1995) . The skewed distribution of HIV-1 g a g t o the VI312 subset was a consistent feature in three samples taken from patient M3 over a 1.3 year period. The VI512 subset was not deleted in M3 or any of our patients (Posnett et al., 1993b) . Therefore, this subset appears to act as a viral reservoir in some patients like M3 (Dobrescu et al., 1995) .
Serum antibodies to CMV were examined in this group of patients (Table 2 ). There was a highly significant correlation between CMV antibodies and high V~12 to V~6.7a viral load ratios (Table 2 ). In contrast, there was no correlation with antibodies to other viruses (Epstein-Barr virus, hepatitis B, and hepatitis C). Thus, CMV infection is associated with HIV-1 DNA selectively enriched in VI312 cells in vivo. (Dobrescu et al., 1995) . ND, not done.
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Is the Vp12-Specific SAG a CMV Product?
To determine whether CMV immediate-early gene products transactivate a host ceLl gene (Stinski, 1978) responsible for the VJ~12 SAG effect, i e l and ie2 were transfected into U937 cells (Figure 9 ). The expression vectors, pON2205 IE1491aa and pON2206 IE2s~gaa (Jenkins et al., 1994) , use the SRa promoter, which lacks the crs cis repression sequence of the iel/ie2 promoter. An alternative transcript for IE2338a~ would also be present in CMV-infected ceils, but not in the IE2~79~-transfected cells. It is expressed as a late gene product and can act as a strong repressor for IE1 and IE2 by binding to crs (Jenkins et al., 1994) . The PCR primers used in Figure 9C amplify a 279 bp fragment of exon 5 shared by both IE2 transcripts. Figures 9B and 9C show that the transfectants expressed mRNA by reverse transcription-PCR (RT-PCR). While infected U937 cells promoted HIV-1 replication specifically in VI312 cells, IE2579aa-transfected cells upregulated HIV-1 replication in all three VI3 subsets tested, and IE1491aa-transfected cells did not augment HIV-1 replication in any subset ( Figure 9A ). The nonspecific HIV-1-activating effect of IE2s~ga~-transfected U937 cells may be repressed in CMV-infected U937 cells.
These results and the failure to detect the SAG effect with NalO4-treated U937 cells together suggest that a CMV-encoded gene is responsible for the SAG effect rather than a transcriptionally activated host cell gene. 10; hepatitis C (HPC) antibodies were measured by ELISA (Abbott); hepatitis B (HPB) antibodies were measured by radioimmunoassay (Abbott). The correlation between CMV serology status and the HIV-1 load was significant: p < 0.0039 by logistical regression analysis. a The ratio was calculated from data on HIV-1 copies per 1000 cells in each V~ subset. Ratios from repeat samples obtained at intervals of 3-9 months are indicated in parentheses. The patients are listed in order of viral load skewing to the V~12 subset. All patients were hemophiliacs except for M1, M3, and 006. The data on viral load have been described previously (Dobrescu et al., 1995) .
Discussion
We demonstrate here that the HIV-1 viral reservoir in V1~12 cells is related to a Vl~12-specific SAG-like activity produced by CMV-infected monocytes. Just as known SAGs, the monocyte-derived SAG directs efficient HIV-1 replication to a specific VI3 subset, perhaps leading to a viral reservoir in these cells. These findings are reminiscent of studies on the role of MMTV SAG (Held et al., 1993 (Held et al., , 1994 .
Previous Examples of Viral SAGs
There are two groups of MMTVs, the infectious exogenous milk-borne retroviruses, which are vertically transmitted, and the endogenous variants, which are integrated in the mouse genome. MMTV sag genes each differ in the C-terminal portion encoding the SAG protein, a type II transmembrane protein. The C-terminal sequence determines the V~ specificity of the SAG and interacts directly with TCR residues (Korman et al., 1992; Acha-Orbea et al., 1993; Marrack et aL, 1993) . Each inbred mouse strain carries a different set of endogenous sag genes and deletes the SAG-targeted VI3 subsets during thymic ontogeny prior to birth. Since the target VI3 subset is required for the exogenous virus to infect the neonatal host successfully (Golovkina et al., 1992; Held et al., 1993) , the evolutionary argument is that mice can protect themselves from infection by integrating the viral sag genes and passing them on to their progeny (Coffin, 1992) . To date, however, integration of dozens of viral sag genes in mice has no parallel in other species. In fact, evidence of endogenous SAGs is lacking in rats and humans Baccala et al., 1992) . Observations on genetic variation in the expressed human VI~ repertoire are apparently due to MHC genes and the TCR genes themselves (Posnett, 1995) .
Another example of a viral SAG has been described, the N protein of the rabies virus nucleocapsid (Lafon et al., 1992 (Lafon et al., , 1994 . The unprocessed SAG binds to MHC class II (z chains and stimulates human VI~8 T cells. In mice, it targets V~6 cells. Mice lacking the VI~6 gene are partially resistant to rabies, as assessed by the absence of clinical paralysis 13 days after infection with rabies virus, and when Vl36 T cells are adoptively transferred, all the mice develop paralysis (Lafon et al., 1994) . It is not known whether natural host animals (foxes, racoons, skunks, bats, coyotes, and wolves) harbor rabies virus with SAG activity and whether their TCR repertoires show V13 deletions typical of endogenous SAGs. It is also not known whether animals lacking the target VI~ subset (Vl36 in selected mice) are less likely to transmit rabies virus to new hosts and whether Vl~-specific activation amplifies the viral load.
A Role for a CMV SAG
We have provided evidence for a CMV-driven SAG that targets human Vl312 cells. While this is likely a CMVencoded gene product (as discussed above), the alternative possibility, that it represents a human endogenous SAG gene transcriptionally activated by CMV infection, is also of interest, as numerous endogenous human retroviruses could possibly serve this function.
A CMV-driven SAG specific for V~12 cells as proposed here would represent the first example of a herpesvirus SAG, with wide-reaching implications for host-pathogen relationships in humans, as several herpesviruses commonly infect the large majority of adults worldwide. A SAG might, for instance, stimulate lymphoproliferation in the infectious mononucleosis syndrome of primary CMV or Epstein-Barr virus (Smith et al., 1993) infection and in primary HIV infection associated with CMV coinfection (Oksenhendler et al., 1993) .
The V1~12 subset does not appear to be preferentially deleted in vivo in CMV-seropositive individuals (Laurence et al., 1992; Posnett et al., 1993b) . In humans, natural exposure to a SAG, such as TSST-1 in toxic shock syndrome, does not lead to persistent detectable deletion of the reactive (V~2) subset (Choi et al., 1990) . Moreover, the putative Vp12-specific SAG may simply not be expressed in persons latently infected with CMV. However, in the setting of in vitro cultures, particularly with NalO4 activation of monocytes, expression of the SAG is likely activated. With HIV infection, CMV genes are known to be transcriptionally activated (Skolnik et al., 1994; Ho et al., 1991) , which might result in SAG production and selective HIV-1 replication in the V1312 subset. In vivo, this would establish an HIV-1 viral reservoir in VI312 cells (Dobrescu et al., 1995) . Future studies need to focus on how these cells escape apoptosis and direct cytopathic effects of HIV-I. The proposed role of the CMV-driven SAG is similar to the role of SAGs produced by exogenous MMTV, which are involved in the amplification of the viral load in the earliest stages of infection after milk-borne vertical transmission of virus from mothers to pups (Golovkina et al., 1992; Held et al., 1993) . However, the MMTV-encoded SAG benefits the original virus, rather than assisting a heterologous virus. Therefore, a role for activated V1312 cells in CMV infection itself is likely.
One idea is that production of infectious CMV from latently infected monocytes requires T cell help. Previous attempts to reactivate latent CMV infection from blood monocytes in vitro have been remarkably unsuccessful (Taylor-Wiedeman et al., 1994) . However, in a culture system of primary monocytes, which relies on contacts with mitogen-stimulated T cells, productive CMV infection was observed (Ibanez et al., 1991) . A SAG could provide the same conditions. By bridging V1~12 cells and monocytes (via TCR and MHC class II) both cell types would be potently activated (Chatila and Geha, 1993) and local concentrations of lymphokines would be elevated. This also occurs in an allo-response in which a large number of T cells bind the allogeneic target cells (via TCR and MHC) . This is in effect what happens in allo-mismatched transplantation, a common clinical scenario for CMV reactivation.
Transactivation of HIV-1 via CMV ie gene products has been suggested as the mechanism for cooperation between CMV and HIV-1 (Davis et al., 1987) . This would require the presence of both transcriptionally active viruses in the same cell, which is probably a rare event (Nelson et al., 1988; Laurence, 1990) . Thus, a firm mechanistic explanation is lacking. CMV-dependent production of a SAG may explain why CMV is a potent cofactor for HIV-1 replication in vitro (Skolnik et al., 1994) . Whether CMV infection accelerates clinical progression of HIV-1 infection (Webster et al., 1989; Hirsch et al., 1984; Rabkin et al., 1993) or increases the susceptibility to HIV infection after initial exposure are questions that deserve further investigation.
Experimental Procedures Cell Cultures and Isolation of Subsets
Peripherat blood mononuclear cells were isolated by density centrifugation. T cells and non-T cells were separated by rosettin 9 with neura-minidase-treated sheep erythrocytes. T cells were infected with HIV-1 TIIIB isolate (moi, 0.05). Non-T cells were treated, where indicated, with 4 mM NalO, (sodium periodate) for 15 rain at 4°C and then irradiated at 3000 rads. Non-T cells were then added back to the infected T cells (106 per milliliter) at a 1:10 ratio (non-T:T) and cultured for 6-8 days in medium containing 10% FCS and IL-2 (50 U of NIH/BRMP per milliter; BTI Research Reagents) added on days 3-4 of culture. V~ subsets were isolated by incubating T cells (106 cells per VI3 MAb) with V~-specific MAb (Posnett et al,, 1993b ) for 45 min, followed by three washes with PBS and a second incubation with goat anti-mouse Ig-coated magnetic beads (Dynal) at 20 beads per target cell for 30 min on ice. Cells adherent to the beads were separated using a magnet and washed with PBS. Cells depteted of a V!3 subset (efficiency, 750/0 -100%) were obtained by collecting the nonadherent cells. Once isolated, the subsets (approximately 104 cells per subset) were immediately lysed to prepare DNA in 50 i 11 of 10 mM Tris (pH 8.0), 1 mM EDTA, 0.001% Triton X-100, 0.0001% SDS, 600 ~.g/ml proteinase K at 56°C for 1 hr, followed by 95°C for 15 min. The isolation of VI~ subsets from patient blood samples was previously described (Dobrescu et al., 1995) .
The mitogen NalO4 had been used to treat non-T feeder cells for maintenance of cloned and uncloned human T cell lines (Laurence et al., 1992) . Fresh non-T ceils from CMV-seropositive donors that are not treated with NaIO4 can provide a strong stimulus for HIV-1 replication in VI312 cells (Dobrescu et al., 1995) . This SAG-like effect is usually augmented after NalO4 stimulation of non-T cells (Dobrescu et al., 1995) , presumably because of nonspecific up-regulation of mRNA in the NalO4-treated cells.
U937 cells were infected with CMV isolates (moi, 1) and cultured for 3 days under the indicated conditions. They were then treated with mitomycin C (50 ~g/ml for 1 hr at 37°C) to inhibit further cell proliferation and were cocultured with freshly HIV-l-infected normal T cells at a cell ratio of 1:10 (or 1:100) for 6-8 days prior to isolation of V~ subsets for PCR.
Viral Isolates and Infections
Three HIV-1 viral isolate stocks were used, TIIIB, JRFL, and BaL, with a concentration of t0 ~ TCID per milliliter. The stocks were prepared in mycoplasma-free CEM cells or in PHA-treated T cell blasts. For infections, 1 x 10 ~ to 5 x 107 freshly isolated T cells were washed twice in PBS and resuspended in 3 ml of RPMI, 10% FCS, and virus was added at an moi of 0.05. The T cells were incubated at 37°C at 5% CO2 for 2 hr. The unincorporated virus was removed by washing three times in PBS, and cells were then cultured under the indicated conditions.
Three CMV viral isolates were used to infect U937 monocytic cells, AD169 (laboratory strain), 1165, and 2830 (clinical isolates from Dr. David Emanuel). U 937 cells (106) were washed once in PBS and resuspended in 1 ml of CMV stock (106 TCID per milliliter), incubated for 2 hr at 37°C at 5% CO2, washed once in PBS, and then cultured for 3 days.
Transfections U937 monocytic cells were grown overnight in RPMI, 10% FCS with antibiotics at a concentration of 0.5 x 106 U937 per milliliter. The U937 cells were then washed in RPMI. U937 cells (3 x 106) resuspended in 0.8 ml of RPMI were transferred to Gene Pulser Cuvettes (Bio-Rad) with 5 #g of DNA and DEAE Dextran (10 p.g/ml), iel and ie2 DNA was prepared from peN2205 and peN2206, kindly donated by Dr. Ed Mokarski (Jenkins et al., 1994) . Cells were electroporated at 250 V, 960 ~F and at a time constant between 12-13.9 s.
HIV-1 PCR
One half of the lysate from each V6 subset (25 ~1) was used for a 50 pl PCR reaction containing 10 mM Tris (pH 9), 50 mM KCI, 0.01% gelatin, 0.1% Triton X-100, 3.5 m M MgCI2, 0.4 mM dNTPs, 2 U of Taq polymerase (Promega), 106 cpm of kinased sense gag primer, 10 ~ cpm of kinased sense HLA-DQe primer, and equal molar ratios of the corresponding unlabeled antisense primers (about 10 pmol of gag primers and 1 pmol of HLA DQ primers per PCR reaction). Primers were labeled with polynucleotide kinase and [~,-32P]ATP (Sambrook et al., 1989) . Primer sequences were as follows: HIV-1 gag (sense), 5'-ATAATCCACCTATCCCAGTAGGAGAAAT-3'; HIV-1 gag (antisense), 5'-TTTGGTCCTTGTCTTATGTCCAGAATG-3'; HLA-DQ~ (sense), 5'-GTGCTGCAGGTGTAAACTTGTACCAG-3'; HLA-DQe (antisense), 5'-CACGGATCCGGTAGCAGCGGTAGAGTT-3'. PCR products were resolved on an 8% polyacrylamide gel and exposed to X-ray film. In each experiment, standard controls were included to quantitate the PCR product. ACH2 cells (104), which contain a single integrated HIV genome per cell (Schnittman et al., 1989) , were diluted 10-fold in a constant number (2 x 10 s) of uninfected CEM cells. The PCR yielded two bands, a gag band (141 bp) and an HLA-DQa band (242 bp), the intensity of which is a nonlinear function of the numbers of HiV-1 copies and the numbers of cell genome copies, respectively.
PCR for CMV Genes
U937 cells (106) were or were not infected with CMV (AD169) and were cultured for 1 or 3 days. At each timepoint, cells were lysed to prepare either genomic DNA (in 50 ~1 of 10 mM Tris [pH 8.0], 1 mM EDTA, 0.001% Triton X-100, 0.0001% SDS, 600 #g/ml proteinase K at 56°C for 1 hr, followed by 95°C for 15 min) or cDNA from RNA preparations of the cells. RNA was extracted after lysis of the U937 cells with RNAzol 8 (Cinna/Biotecx Laboratories Incorporated). cDNA was prepared in a 200 ~1 final volume in 1 x first strand buffer, 5 mM MgCI2, 0.5 mM dNTPs, 4 U/p.I RT, 0.5 U/pl RNasin (Promega), and 2.5 p.M d(N)6 (Gene Link).
Genomic DNA and cDNA were used for a 50 I~1 PCR reaction containing 10 mM Tris (pH 9), 50 mM KCI, 0.01% gelatin, 0.1% Triton X-100, 4 mM MgCIz, 0.5 mM dNTPs, 2 U of Taq polymerase (Promega), and 10 pmol of each primer.
PCR primers for iel were as follows: (exon 2), 5'-TTCTATGCCGCA-CCATGTCC-3'; (exon 4), 5-'TGGAGTCCTCTGCCAAGAGA-3' (PCR fragment is 581 bp for genomic DNA and 297 bp for cDNA); ie2 (exon 5), 5-'CGTTGTCCAACTCGGAGATG-3'; (exon 5), 5'-ACCACCCTCCT-CTTCCCGAT-3' (PCR fragment is 279 bp).
